Sign up now to receive our regular news briefs.

Israeli Start-Up Alcobra Develops New Treatment for Attention Deficit Disorder

December 2, 2013 3:26 pm 2 comments
Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israeli pharmaceutical start-up Alcobra Pharmaceuticals is listed on the NASDAQ electronic stock exchange under the ticker ADHD, the disease it treats with a non-stimulant compound that is expected to come to the market in 2015.

In an interview with Israeli business daily Globes, CEO Dr. Yaron Daniely explained how the company was originally created in 2008 to develop the molecule metadoxine to help inhibit the effects of alcohol on the brain.

“The goal was to create a pill that would quickly reduce blood alcohol levels, so that people would be able to drive safely,” explains Daniely. “It turned out the drug had no significant impact on removing alcohol from the blood, but it had a very significant impact on cognitive ability. In driving, memory, and attention tests that were conducted, it was as though those people were not drunk, despite the fact that, in terms of the amount of alcohol in their blood, it was not clear that they would be able to stand on their own two feet. So the idea to treat Attention Deficit Disorder came about.”

A pilot the company conducted in 2010 among 40 adults with ADHD showed “an immediate and significant improvement in attention tests. As a result of this, the company reinvented itself,” Daniely said, which is when he was named by researchers Dr. Dalia Megiddo and Udi Gilboa to be its new CEO.

Bilingual with a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine, an NIH Visiting Fellow in Cell Biology, a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science, in Rehovot, and an MBA from the Technion – Israel Institute of Technology, Daniely also was VP Business Development at Gamida Cell Ltd., managing its joint venture with Teva Pharmaceutical Industries Ltd.(NYSE: TEVA; TASE: TEVA) to develop a cancer drug.

The idea was to approach TEVA to fund the start-up, which it did with $5 million to fund its first tests. But with TEVA later in a management crisis, and its options to increase its position in Alcobra expired, the team sought an IPO on the NASDAQ, which has since net it some $60 million in proceeds and a market capitalization of $220 million, more than enough to fund its final tests and market launch.

Daniely said the chemical compound metadoxine has been approved for 40 years for the treatment of liver disease in third-world countries, including India, China, Russia, and Thailand. The company has registered a patent for the use of metadoxine for neurological conditions, through a timed-release of the substance, so its effect on the patient lasts a few hours.

Globes said that Alcobra has no labs, its raw materials are manufactured by a third party in Germany, and the pills themselves are manufactured in the US. The company believes that the drug combines the benefits of the two existing classes of ADHD drugs – the stimulants, such as Ritalin and Concerta, and the non-stimulant drugs, such as Strattera – and claims that it does not have their drawbacks.

According to the company, the results of the clinical trials showed that the drug is not addictive, worked faster and was twice as effective as the existing non-stimulant drugs, and had a similar anti-ADHD effect to that of the stimulants. It primarily affects cognitive ability, less so hyperactivity.

Daniely advised other Israeli start-ups to follow four lessons from Alcobra’s successful IPO. “The first element was quality, and a refusal to compromise,” he said. “Alcobra, from day one, tried to be different from other companies. We have an almost pedantic stubbornness not to do things too small or too short, but rather to do the things the way we would if we were a company in Silicon Valley. Therefore, our Phase II trial didn’t include 20 people over two weeks, instead, it included 120 people, with a placebo control, over the course of six weeks, using the exact same measures that all the ADHD drugs in the world are measured by. Many companies understand too late that they are conducting poorer trials without the appropriate controls.”

The second element was the company’s target market. “There’s nothing like ADHD,” he says. “First of all, people understand the market; there are drugs, it is known how much each company is selling and why, there are patients, there is a market that turns over $4 billion each year in the US. Also, people think they understand what ADHD is. It affects almost everyone, their kid, or their nephew.”

A third element is the pace of development: “With ADHD, unlike rare cancers, participants for clinical trials are incredibly easy to find. So our time to market and our ability to build our development process are such that almost every month we have good news for shareholders. The phase III trial will include 300 patients, in 20 medical centers, over the course of six months.”

The fourth element that helped secure funding was his native-English speaking ability, personal CV and track record and a decision to invite well-known professionals from the ADHD research community to be on their team, in this case, Prof. Lenard Adler, a researcher from NYU and an expert in ADHD drug development, who serves as head of the clinical committee that advises the company. “When someone like him sits next to you and says: ‘I conducted the trial and I stand behind the results,’ they can’t blow you off. Israeli entrepreneurs need to understand this and bring these people to their companies, so they can bridge the gap,” Daniely said.

While the company tried to get funding in Israel, where ADHD is less frequently diagnosed, its success in raising money on the NASDAQ has led many other young pharma companies to its doors, seeking advice. Its success has also led to new projects.

“Many things happened at the company, and our ability to implement plans grew. We had a tremendous opportunity to treat fragile X syndrome, which is associated with autism. It is a very common condition, which is very difficult for many who suffer from it, and there is no treatment. In a trial we conducted on animals with a kind of fragile X, we came up with outstanding results. It completely normalized learning, memory, social behavior, and communication. In parallel, the market in the US was still on fire, and said, ‘go, secure the investment, and bring in more cash,'” Daniely said.

The funds Alcobra raised guarantee that the company will have full funding until it is approved as a drug for adult ADHD, which, according to Daniely, is expected to reach market in late 2015, and for children soon afterwards. The money will also fund the fragile X trial.

2 Comments

  • In this period of financial crisis, you usually do not have to spend huge amount of money just to find out girls
    get their clothes off in front individuals. You have to discover once the nude models from the sex chat website can be extremely beautiful and
    deliciously attractive. Military husbands stationed in the Middle
    East have been in a position to witness the birth of an youngster through webcams.

  • Davida Rosenberg

    Please update me when this will be available in the U.S.
    A family member age 36 male.. has suffered his whole young life with this condition.

Leave a Reply

Please note: comments may be published in the Algemeiner print edition.


Current day month ye@r *

More...

  • Relationships US & Canada Analysis: Jewish Women Less Likely Than Catholics to Take Husband’s Name

    Analysis: Jewish Women Less Likely Than Catholics to Take Husband’s Name

    An analysis of New York Times wedding announcements showed that women married in Jewish ceremonies were less likely to take their husband’s last names than those married in Roman Catholic ceremonies, the Times reported on Saturday. The largest gap between the two groups was in 1995 when 66 percent of Catholic women took their husband’s names and 33 percent of Jewish women did the same. Nearly half of the women featured in the publication’s wedding pages since 1985 took their husband’s name after marriage, while about […]

    Read more →
  • Arts and Culture Blogs Jerry Lewis, Legendary Jewish Comic and Humanitarian, Stays Relevant at 89

    Jerry Lewis, Legendary Jewish Comic and Humanitarian, Stays Relevant at 89

    JNS.org – Through appreciation of both his comedy and humanitarian work, legendary Jewish entertainer Jerry Lewis is staying relevant at age 89. The only comic to ever be nominated for a Nobel Peace Prize, Lewis added another award to his trophy case in April, when he received the 2015 Distinguished Service Award from the National Association of Broadcasters (NAB). Gordon Smith, NAB’s president and CEO, said the organization was “honored to recognize not only [Lewis’s] comedic innovation, but also his remarkable […]

    Read more →
  • Europe Sports Israeli Gymnasts Win Bronze, Silver Medals at 2015 European Games in Baku

    Israeli Gymnasts Win Bronze, Silver Medals at 2015 European Games in Baku

    Israeli athletes marked a successful day on Sunday, as gymnasts won multiple bronze and silver medals in the 2015 European Games in Baku. The Gymnastics team won two silver medals and one bronze in group events, while Neta Rivkin, an Israeli Olympic gymnast, won bronze for the Solo Hoops event. Sunday’s gymnastics wins follow Sergey Richter’s bronze on June 16 for the Men’s 10 meter air-rifle, and Ilana Kratysh’s silver for women’s freestyle wrestling. The 2015 European Games in Baku are […]

    Read more →
  • Theater Report Highlights Success of Russian-Jewish-American Ballroom Dancers

    Report Highlights Success of Russian-Jewish-American Ballroom Dancers

    Russian-American Jews are some of the most successful ballroom dancing competitors in the U.S., South Dakota Public Broadcasting (SDPB) Radio reported on Thursday. Jonathan Sarna, a professor of Jewish history at Brandeis University, said their success can be traced back to Jewish discrimination in the former Soviet Union. Because of the prejudice they faced, Russian Jews had to perform better than their peers in every field, including dancing, in order to have a chance of getting ahead. “They knew that if they […]

    Read more →
  • Arts and Culture US & Canada Israeli Dancer With Shofar, Prayer Shawl Wows ‘So You Think You Can Dance’ Judges (VIDEO)

    Israeli Dancer With Shofar, Prayer Shawl Wows ‘So You Think You Can Dance’ Judges (VIDEO)

    An Israeli dancer made use of Jewish props in an extraordinary routine that left judges amazed when he auditioned for season 12 of TV dance competition So You Think You Can Dance on Monday. At first, the panel of judges appeared confused when Asaf Goren, 23, began his audition in Los Angeles with a tallit (prayer shawl) over his head and the blowing of a shofar, which he explained “opens the sky” for people’s prayers. However, as soon as he started his “Hebrew breaking” performance, […]

    Read more →
  • Sports US & Canada Jewish Hoops Fairytale Falls Short as David Blatt’s Cavaliers Drop Game 6

    Jewish Hoops Fairytale Falls Short as David Blatt’s Cavaliers Drop Game 6

    JNS.org – A fairytale ending to Jewish basketball coach David Blatt’s first season in the National Basketball Association (NBA) was not meant to be, as the Blatt-led Cleveland Cavaliers on Tuesday night dropped Game 6 of the NBA Finals to the Golden State Warriors, 105-97, to lose the best-of-seven series 4-2. Blatt, who just last year coached Israel’s Maccabi Tel Aviv franchise to a European basketball championship, failed to finish a second straight hoops season on top. But after the Cavaliers began the NBA […]

    Read more →
  • Blogs Sports Israelis Venture to Cleveland for NBA Finals

    Israelis Venture to Cleveland for NBA Finals

    JNS.org – The people who sat in seats one and two of row 12, section 120 at Quicken Loans Arena during Game 3 of the NBA Finals on Tuesday night weren’t your ordinary Cleveland Cavaliers fans. Tomer Hulli and his father, Eli, made the trip from Israel to attend games 3 and 4 in Cleveland. Tomer, who lives in Tzur Moshe, a 25-minute drive north of Tel Aviv, has been playing basketball since he was 5. Hulli said he didn’t plan this […]

    Read more →
  • Arts and Culture Israel Bon Jovi Signs Contract to Perform in Israel

    Bon Jovi Signs Contract to Perform in Israel

    JNS.org – The American rock band Bon Jovi signed a contract in Germany that officially commits it to perform in Israel on Oct. 3, the concert’s producers announced at a press conference. The move marks the latest defeat for Boycott, Divestment and Sanctions movement activists seeking to convince musicians not to perform in the Jewish state. Bon Jovi’s performance in Israel for the final show of its Asian concert tour is the result of an effort by Guy Besser and Shay Mor Yosef of BlueStone Productions, in cooperation with promoter Marcel […]

    Read more →